Abstract
Evidence has been provided that circulating cancer-associated macrophage-like cell (CAM-L) numbers increase in response to chemotherapy, with an inverse trend compared to circulating tumor cells (CTCs). In the era of evolving cancer immunotherapy, whether CAM-Ls might have a potential role as predictive biomarkers of response has been unexplored. We evaluated whether a serial blood evaluation of CTC to CAM-L ratio might predict response to immune checkpoint inhibitors in a cohort of non-small-cell lung cancer patients. At baseline, CTCs, CAM-Ls, and the CTC/CAM-L ratio significantly correlate with both progression-free survival (PFS) and overall survival (OS). The baseline CTC/CAM-L ratio was significantly different in early progressors (4.28 ± 3.21) compared to long responders (0.42 ± 0.47) (p = 0.001). In patients treated with immune checkpoint inhibitors, a CTC/CAM-L ratio ≤ 0.25 at baseline is associated with better PFS and OS. A baseline CTC/CAM-L ratio ≤ 0.25 is statistically significant to discriminate early progressions from durable response. The results of the present pilot study suggest that CAM-Ls together with CTCs could play an important role in evaluating patients treated with cancer immunotherapy.
Funding Information
  • Sapienza University of Rome (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
  • European Commission (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
  • ECS 0000024 Rome Technopole (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)
  • European Union–NextGenerationEU (RM11916B31436754, PE_00000019, CUP B53C22004000006, CUP B83C22002820006)

This publication has 36 references indexed in Scilit: